Roivant Sciences Ltd. (ROIV) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en London, United Kingdom. El CEO actual es Matthew Gline.
ROIV tiene fecha de IPO 2020-12-08, 908 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $20.84B.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company headquartered in London that researches and develops innovative medicines across multiple therapeutic areas. The company's pipeline includes product candidates targeting oncologic malignancies, rare genetic disorders such as sickle cell disease and hypophosphatasia, and various inflammatory and dermatological conditions including psoriasis, atopic dermatitis, and vitiligo. Additional focus areas encompass autoimmune diseases, ophthalmologic disorders, and infectious diseases. Founded in 2014, Roivant combines drug development expertise with healthcare technology capabilities to address significant unmet medical needs globally.
